Clinical data | |
---|---|
Trade names | Velban, Velbe, others |
Other names | vincaleukoblastine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682848 |
License data |
|
Pregnancy category |
|
Routes of administration | intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Metabolism | Liver (CYP3A4-mediated) |
Elimination half-life | 24.8 hours (terminal) |
Excretion | Bile duct and kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.011.577 |
Chemical and physical data | |
Formula | C46H58N4O9 |
Molar mass | 810.989 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Vinblastine (VBL), sold under the brand name Velban among others, is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer.[1] This includes Hodgkin's lymphoma, non-small-cell lung cancer, bladder cancer, brain cancer, melanoma, and testicular cancer.[1] It is given by injection into a vein.[1]
Most people experience some side effects.[1] Commonly it causes a change in sensation, constipation, weakness, loss of appetite, and headaches.[1] Severe side effects include low blood cell counts and shortness of breath.[1] It should not be given to people who have a current bacterial infection.[1] Use during pregnancy will likely harm the baby.[1] Vinblastine works by blocking cell division.[1]
Vinblastine was isolated in 1958.[2] An example of a natural herbal remedy that has since been developed into a conventional medicine, vinblastine was originally obtained from the Madagascar periwinkle.[3] It is on the World Health Organization's List of Essential Medicines.[4]